

Angelo Antonini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7679200/angelo-antonini-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

552
papers

27,066
citations

85
h-index

139
g-index

623
ext. papers

31,023
ext. citations

4.9
avg, IF

6.84
L-index

#	Paper	IF	Citations
552	Subthalamic deep brain stimulation in Parkinson's disease with SNCA mutations: Based on the follow-up to 10 years.. <i>Brain and Behavior</i> , 2022 , e2503	3.4	1
551	Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.. <i>BMC Neurology</i> , 2022 , 22, 35	3.1	1
550	Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries.. <i>Neurology and Therapy</i> , 2022 , 11, 303	4.6	1
549	Early Compensatory Mechanisms in LRRK2 Mutation Carriers.. <i>Movement Disorders</i> , 2022 ,	7	
548	Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.. <i>Npj Parkinsons Disease</i> , 2022 , 8, 17	9.7	0
547	Antiphospholipid-Related Chorea: Two Case Reports and Role of Metabolic Imaging.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 516-521	2.2	0
546	Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.. <i>BMC Neurology</i> , 2022 , 22, 88	3.1	0
545	Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 479-483	2.2	0
544	Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.. <i>Movement Disorders</i> , 2022 ,	7	2
543	Gender gap in deep brain stimulation for Parkinson's disease.. <i>Npj Parkinsons Disease</i> , 2022 , 8, 47	9.7	0
542	Action Selection and Motor Decision Making: Insights from Transcranial Magnetic Stimulation. <i>Brain Sciences</i> , 2022 , 12, 639	3.4	0
541	Personalized Care in Late-Stage Parkinson's Disease: Challenges and Opportunities. <i>Journal of Personalized Medicine</i> , 2022 , 12, 813	3.6	0
540	Spotlight on non-motor symptoms and Covid-19. <i>International Review of Neurobiology</i> , 2022 ,	4.4	
539	Remote Evaluation of Parkinson's Disease Using a Conventional Webcam and Artificial Intelligence.. <i>Frontiers in Neurology</i> , 2021 , 12, 742654	4.1	1
538	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Analysis of BIPARK-I and -II. <i>Frontiers in Neurology</i> , 2021 , 12, 754016	4.1	0
537	Impairment of human dopaminergic neurons at different developmental stages by perfluoro-octanoic acid (PFOA) and differential human brain areas accumulation of perfluoroalkyl chemicals. <i>Environment International</i> , 2021 , 158, 106982	12.9	3
536	Education on palliative care for Parkinson patients: development of the "Best care for people with late-stage Parkinson's disease" curriculum toolkit. <i>BMC Medical Education</i> , 2021 , 21, 538	3.3	2

535	Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications. <i>Parkinsonism and Related Disorders</i> , 2021 , 92, 59-66	3.6	4
534	Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 322-340 ²		3
533	Parkinson's Disease and Post-COVID-19 Syndrome: The Parkinson's Long-COVID Spectrum. <i>Movement Disorders</i> , 2021 , 36, 1287-1289	7	29
532	The impact of COVID-19 on palliative care for people with Parkinson's and response to future pandemics. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 615-623	4.3	7
531	Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. <i>Parkinsonism and Related Disorders</i> , 2021 , 86, 124-132	3.6	5
530	Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. <i>Npj Parkinsons Disease</i> , 2021 , 7, 43	9.7	8
529	Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies. <i>Movement Disorders</i> , 2021 , 36, 1781-1791	7	5
528	The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review. <i>Advances in Therapy</i> , 2021 , 38, 2854-2890	4.1	9
527	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. <i>Npj Parkinsons Disease</i> , 2021 , 7, 48	9.7	9
526	Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 2303-2313	7	3
525	Comparison of self-reported symptoms and psychophysical tests in coronavirus disease 2019 (COVID-19) subjects experiencing long-term olfactory dysfunction: a 6-month follow-up study. <i>International Forum of Allergy and Rhinology</i> , 2021 , 11, 1592-1595	6.3	5
524	Movement perception of the tonic vibration reflex is abnormal in functional limb weakness. <i>Parkinsonism and Related Disorders</i> , 2021 , 87, 1-6	3.6	1
523	Moving towards Integrated and Personalized Care in Parkinson's Disease: A Framework Proposal for Training Parkinson Nurses. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	3
522	Oscillatory EEG-TMS Reactivity in Parkinson Disease. <i>Journal of Clinical Neurophysiology</i> , 2021 ,	2.2	2
521	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. <i>Movement Disorders</i> , 2021 , 36, 681-689	7	11
520	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic" neurology. <i>European Journal of Neurology</i> , 2021 , 28, 1752-1758	6	14
519	Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. <i>Journal of Parkinsons Disease</i> , 2021 , 11, 323-335	5.3	10
518	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , 2021 , 268, 448-454	5.5	11

517	The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. <i>Acta Neurologica Scandinavica</i> , 2021 , 143, 3-12	3.8	16
516	The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. <i>Brain Communications</i> , 2021 , 3, fcab180	4.5	5
515	Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease. <i>Current Neuropharmacology</i> , 2021 , 19, 1618-1639	7.6	2
514	TaSCA, an Agile Survey on Chemosensory Impairments for Self-Monitoring of COVID-19 Patients: A Pilot Study. <i>Frontiers in Neurology</i> , 2021 , 12, 633574	4.1	1
513	Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. <i>Parkinsonism and Related Disorders</i> , 2021 , 89, 186-194	3.6	3
512	Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	10
511	Access and Attitudes Toward Palliative Care Among Movement Disorders Clinicians. <i>Movement Disorders</i> , 2021 ,	7	4
510	Impact of social and mobility restrictions in Parkinson's disease during COVID-19 lockdown. <i>BMC Neurology</i> , 2021 , 21, 332	3.1	6
509	Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregivers-Study Protocol for a Multicentre, Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2021 , 12, 673893	4.1	2
508	The Parkinson's Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson's Disease in Patients and their Carers. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 1309-1323	5.3	2
507	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. <i>Journal of Neurology</i> , 2021 , 1	5.5	1
506	Consensus on the treatment of dysphagia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2021 , 430, 120008	3.2	2
505	Reduced Effective Connectivity in the Motor Cortex in Parkinson's Disease. <i>Brain Sciences</i> , 2021 , 11,	3.4	2
504	Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy". <i>Movement Disorders</i> , 2021 , 36, 2208-2209	7	
503	Quantification of Brain β Amyloid Load in Parkinson's Disease With Mild Cognitive Impairment: A PET/MRI Study.. <i>Frontiers in Neurology</i> , 2021 , 12, 760518	4.1	0
502	Fractal Analysis of Lower Back Acceleration Profiles in balance tasks. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2021 , 2021, 7381-7384	0.9	
501	Data-assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2020 , 16, e043593	1.2	
500	The reliability of a deep learning model in external memory clinic MRI data: A multi-cohort study. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042969	1.2	

499	Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden. <i>Neuropsychiatric Disease and Treatment</i> , 2020 , 16, 2899-2912	3.1	3
498	Anatomy and Connectivity of the Subthalamic Nucleus in Humans and Non-human Primates. <i>Frontiers in Neuroanatomy</i> , 2020 , 14, 13	3.6	12
497	A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 687-694	5.5	16
496	Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 685-695	5.9	13
495	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. <i>Medical Image Analysis</i> , 2020 , 66, 101714	15.4	26
494	Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey. <i>Journal of Neural Transmission</i> , 2020 , 127, 875-879	4.3	8
493	Dyskinesia Matters: But Not as Much as It Used to. <i>Movement Disorders</i> , 2020 , 35, 900-901	7	1
492	Health care for chronic neurological patients after COVID-19. <i>Lancet Neurology, The</i> , 2020 , 19, 562-563	24.1	2
491	Predictors of Response for "Off" Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry. <i>Frontiers in Neurology</i> , 2020 , 11, 419	4.1	2
490	Comment on "The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis". <i>Otolaryngology - Head and Neck Surgery</i> , 2020 , 163, 852	5.5	5
489	Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson's disease. <i>Journal of Neurology</i> , 2020 , 267, 1830-1841	5.5	12
488	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2020 , 127, 881-891	4.3	2
487	Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving 2000 mg Daily Dose of Levodopa. <i>Parkinson's Disease</i> , 2020 , 2020, 9716317	2.6	6
486	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. <i>Movement Disorders</i> , 2020 , 35, 976-983	7	20
485	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020 , 35, 650-661	7	14
484	Outcome of Parkinson's Disease Patients Affected by COVID-19. <i>Movement Disorders</i> , 2020 , 35, 905-9087		120
483	Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population. <i>Neurological Sciences</i> , 2020 , 41, 2929-2937	3.5	2
482	Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2020 , 8, e16414	5.5	17

481	Foot Pressure Wearable Sensors for Freezing of Gait Detection in Parkinson's Disease. <i>Sensors</i> , 2020 , 21,	3.8	13
480	Efficacy, safety and patient's quality of life of long-term treatment with levodopa-carbidopa intestinal gel in advanced Parkinson's disease in Romania: Results from GLORIA observational study 2020 , 19, 27-35		4
479	New routes of dopaminergic drug delivery in patients with Parkinson's disease. <i>Lancet Neurology, The</i> , 2020 , 19, 105-106	24.1	
478	Differences in cognitive profiles between Lewy body and Parkinson's disease dementia. <i>Journal of Neural Transmission</i> , 2020 , 127, 323-330	4.3	6
477	Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease. <i>Brain Stimulation</i> , 2020 , 13, 1697-1705	5.1	17
476	Patient-centred management of Parkinson's disease. <i>Lancet Neurology, The</i> , 2020 , 19, 887-888	24.1	0
475	Incentive-driven decision-making networks in de novo and drug-treated Parkinson's disease patients with impulsive-compulsive behaviors: A systematic review of neuroimaging studies. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 165-177	3.6	4
474	Moving towards home-based community-centred integrated care in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 21-26	3.6	9
473	Prevalence of Extrapyrarnidal Symptoms in In-Patients With Severe Mental Illnesses: Focus on Parkinsonism. <i>Frontiers in Neurology</i> , 2020 , 11, 593143	4.1	2
472	Technology-Enabled Care: Integrating Multidisciplinary Care in Parkinson's Disease Through Digital Technology. <i>Frontiers in Neurology</i> , 2020 , 11, 575975	4.1	11
471	Reply to: "Concerns Raised by Publication of Antonini et al., 'Outcome of Parkinson Disease Patients Affected by Covid-19'". <i>Movement Disorders</i> , 2020 , 35, 1298	7	1
470	Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. <i>Neurodegenerative Disease Management</i> , 2020 , 10, 309-323	2.8	14
469	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 920-929	2.2	20
468	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 750-762	2.2	13
467	COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. <i>Npj Parkinson's Disease</i> , 2020 , 6, 18	9.7	66
466	Deep brain stimulation for monogenic Parkinson's disease: a systematic review. <i>Journal of Neurology</i> , 2020 , 267, 883-897	5.5	15
465	Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. <i>Movement Disorders</i> , 2020 , 35, 171-176	7	23
464	Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 361-372	2.2	55

463	Deep brain stimulation in Parkinson's disease: A multicentric, long-term, observational pilot study. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 116411	3.2	4
462	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019 , 142, 3592-3604	11.2	54
461	Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. <i>Neurology</i> , 2019 , 93, 630-639	6.5	38
460	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 353-365	7	80
459	Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. <i>Journal of Neurology</i> , 2019 , 266, 2164-2176	5.5	27
458	Long-term effect of subthalamic and pallidal deep brain stimulation for status dystonicus in children with methylmalonic acidemia and GNAO1 mutation. <i>Journal of Neural Transmission</i> , 2019 , 126, 739-757	4.3	12
457	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019 , 34, 975-984	7	44
456	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019 , 34, 1228-1232	7	56
455	Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019 , 10, 266	4.1	6
454	Dysphagia predicts poor outcome in late-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 64, 73-81	3.6	14
453	Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?. <i>Movement Disorders</i> , 2019 , 34, 816-819	7	30
452	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 301-309	5.2	14
451	Frontal and subcortical contribution to visual hallucinations in dementia with Lewy bodies and Parkinson's disease. <i>Postgraduate Medicine</i> , 2019 , 131, 509-522	3.7	11
450	Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019 , 126, 1437-1445	4.3	12
449	Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety. <i>Journal of Parkinson's Disease</i> , 2019 , 9, 531-541	5.3	20
448	Dynamic functional connectivity changes associated with dementia in Parkinson's disease. <i>Brain</i> , 2019 , 142, 2860-2872	11.2	81
447	The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson's disease. <i>European Journal of Neurology</i> , 2019 , 26, 1327-1333	6	13
446	Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 1203-1218	4.1	19

445	Risk factors for impulse control disorders and related behaviors in Parkinson's disease: secondary analyses of the ICARUS study. <i>Journal of Drug Assessment</i> , 2019 , 8, 159-166	1.5	3
444	Reply: Dynamic functional connectivity changes in Lewy body disease. <i>Brain</i> , 2019 , 142, e69	11.2	1
443	mHealth Platform for Parkinson's Disease Management. <i>IFMBE Proceedings</i> , 2019 , 29-35	0.2	1
442	Influence of disease severity in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 211	3.2	
441	Efficacy of opicapone in Parkinson's disease patients according to baseline presence of dyskinesia: A post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 192	3.2	
440	Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens". <i>Movement Disorders</i> , 2019 , 34, 1930-1931	7	2
439	Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson's disease patients: Post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 203	3.2	
438	Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. <i>Neurodegenerative Disease Management</i> , 2019 , 9, 39-46	2.8	13
437	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2019 , 15, 400-409	1.2	36
436	Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 57-64	2.2	12
435	Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel. <i>European Journal of Neurology</i> , 2019 , 26, 581-e43	6	13
434	Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson's disease patients. <i>Brain Imaging and Behavior</i> , 2019 , 13, 232-240	4.1	15
433	Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 421-430	7	52
432	Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study. <i>Journal of Neurology</i> , 2018 , 265, 1124-1137	5.5	31
431	Pain in Parkinson's disease: facts and uncertainties. <i>European Journal of Neurology</i> , 2018 , 25, 917-e69	6	46
430	Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease. <i>Brain Stimulation</i> , 2018 , 11, 867-874	5.1	28
429	Medical and surgical management of advanced Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 900-908		76
428	Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2018 , 8, 161-170	2.8	12

427	Relevance of sleep quality on caregiver burden in Parkinson's disease. <i>Neurological Sciences</i> , 2018 , 39, 835-839	3.5	20
426	DBS for Parkinson's disease with behavioural disturbances. <i>Lancet Neurology</i> , 2018 , 17, 195-197	24.1	4
425	Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease. <i>Neuromodulation</i> , 2018 , 21, 532-540	3.1	21
424	Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts. <i>Brain Stimulation</i> , 2018 , 11, 904-912	5.1	28
423	Nutritional habits, risk, and progression of Parkinson disease. <i>Journal of Neurology</i> , 2018 , 265, 12-23	5.5	33
422	Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. <i>Journal of Neural Transmission</i> , 2018 , 125, 1131-1135	4.3	19
421	Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. <i>Current Medical Research and Opinion</i> , 2018 , 34, 2063-2073	2.5	82
420	Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018 , 4, 14	9.7	49
419	A decision support system for Parkinson disease management: expert models for suggesting medication change. <i>Journal of Decision Systems</i> , 2018 , 27, 164-172	1.2	10
418	Disease progression in Parkinson subtypes: the PPMI dataset. <i>Neurological Sciences</i> , 2018 , 39, 1971-1976	3.5	33
417	Peri-electrode edema after bilateral subthalamic deep brain stimulation for Parkinson's disease. <i>Journal of Neurosurgical Sciences</i> , 2018 , 62, 103-105	1.3	1
416	Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age. <i>Movement Disorders</i> , 2018 , 33, 99-107	7	32
415	USP14 inhibition corrects an model of impaired mitophagy. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	45
414	Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 229-237	4.3	19
413	Apomorphine infusion in advanced Parkinson disease. <i>Nature Reviews Neurology</i> , 2018 , 14, 693-694	15	8
412	Regulation of ER-mitochondria contacts by Parkin via Mfn2. <i>Pharmacological Research</i> , 2018 , 138, 43-56	10.2	97
411	Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial. <i>Trials</i> , 2018 , 19, 492	2.8	17
410	First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire. <i>European Journal of Neurology</i> , 2018 , 25, 1255-1261	6	14

409	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. <i>Parkinsonism and Related Disorders</i> , 2017 , 38, 90-92	3.6	35
408	The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease. <i>European Journal of Neurology</i> , 2017 , 24, 788-795	6	29
407	Distribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale. <i>Npj Parkinson's Disease</i> , 2017 , 3, 8	9.7	22
406	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017 , 32, 995-1005	7	88
405	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017 , 32, 955-971	7	127
404	Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017 , 41, 113-117	3.6	12
403	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017 , 32, 853-864	7	840
402	Relationship between pain and motor and non-motor symptoms in Parkinson's disease. <i>European Journal of Neurology</i> , 2017 , 24, 974-980	6	16
401	Device-Aided Treatment Strategies in Advanced Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 132, 453-474	4.4	18
400	Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. <i>NeuroImage: Clinical</i> , 2017 , 14, 734-740	5.3	54
399	Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. <i>Parkinsonism and Related Disorders</i> , 2017 , 39, 37-43	3.6	29
398	The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. <i>Movement Disorders</i> , 2017 , 32, 510-525	7	65
397	ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 317-324	5.5	82
396	Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible?. <i>Archives of Clinical Neuropsychology</i> , 2017 , 32, 840-860	2.7	26
395	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. <i>Parkinsonism and Related Disorders</i> , 2017 , 45, 13-20	3.6	93
394	Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study. <i>Movement Disorders</i> , 2017 , 32, 1557-1565	7	50
393	Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017 , 7, 491-501	5.3	29
392	Understanding and Treating Pain Syndromes in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 134, 827-858	4.4	16

391	PD_Manager: an mHealth platform for Parkinson's disease patient management. <i>Healthcare Technology Letters</i> , 2017 , 4, 102-108	1.9	37
390	Cognitive impairment in multiple system atrophy. <i>Movement Disorders</i> , 2017 , 32, 1338-1339	7	15
389	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. <i>ENeurologicalSci</i> , 2017 , 8, 44-53	2.1	7
388	Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions. <i>International Review of Neurobiology</i> , 2017 , 133, 389-415	4.4	7
387	Predicting rapid progression of Parkinson's Disease at baseline patients evaluation. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2017 , 2017, 3898-3901	0.9	3
386	An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients. <i>Advances in Therapy</i> , 2017 , 34, 1741-1752	4.7	18
385	Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists. <i>World Neurosurgery</i> , 2017 , 99, 41-46	2.1	36
384	Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. <i>European Radiology</i> , 2017 , 27, 2665-2675	8	46
383	Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>Journal of Neural Transmission</i> , 2017 , 124, 293-302	4.3	36
382	Water-based vs. non-water-based physiotherapy for rehabilitation of postural deformities in Parkinson's disease: a randomized controlled pilot study. <i>Clinical Rehabilitation</i> , 2017 , 31, 1107-1115	3.3	25
381	A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. <i>Journal of Parkinson's Disease</i> , 2017 , 7, 533-543	5.3	31
380	The End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 330	5.3	17
379	Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017 , 8, 432	4.1	31
378	Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016 , 123, 57-64	4.3	87
377	Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. <i>Brain Stimulation</i> , 2016 , 9, 78-85	5.1	71
376	Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. <i>Parkinsonism and Related Disorders</i> , 2016 , 32, 108-115	3.6	15
375	Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. <i>Neurological Sciences</i> , 2016 , 37, 1785-1792	3.5	20
374	Monitoring of motor and non-motor symptoms of Parkinson's disease through a mHealth platform. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2016 , 2016, 663-666	0.9	16

373	Tremor UPDRS estimation in home environment. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference, 2016, 2016, 3642-3645</i>	0.9	10
372	Cognitive decline in Parkinson's disease: the complex picture. <i>Npj Parkinsons Disease, 2016, 2, 16018</i>	9.7	65
371	Italian survey on intraduodenal levodopa gel treatment in advanced Parkinson disease: State of the art 10 years after marketing. <i>Parkinsonism and Related Disorders, 2016, 22, e97-e98</i>	3.6	
370	The First Parkinson's Disease Pain Questionnaire (King's PD Pain Quest) – An interim analysis of a multicentre study of the patient's perspective. <i>Parkinsonism and Related Disorders, 2016, 22, e41</i>	3.6	2
369	The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature. <i>Journal of Neural Transmission, 2016, 123, 241-50</i>	4.3	34
368	MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission, 2016, 123, 431-8</i>	4.3	76
367	Do patients with late-stage Parkinson's disease still respond to levodopa?. <i>Parkinsonism and Related Disorders, 2016, 26, 10-6</i>	3.6	44
366	Therapy-resistant symptoms in Parkinson's disease. <i>Journal of Neural Transmission, 2016, 123, 19-30</i>	4.3	21
365	Dopaminergic Medication Modulates Learning from Feedback and Error-Related Negativity in Parkinson's Disease: A Pilot Study. <i>Frontiers in Behavioral Neuroscience, 2016, 10, 205</i>	3.5	7
364	Globus pallidus internus deep brain stimulation for the treatment of status dystonicus in tardive dystonia. <i>Acta Neurochirurgica, 2016, 158, 1789-91</i>	3	9
363	tDCS effect on cognitive performance in Parkinson's disease. <i>Movement Disorders, 2016, 31, 1253-4</i>	7	4
362	Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. <i>Journal of Neural Transmission, 2016, 123, 1435-1442</i>	4.3	39
361	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology, 2016, 23, 1255-61</i>	6	58
360	Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease. <i>Acta Neurologica Scandinavica, 2016, 133, 451-8</i>	3.8	21
359	Apathy in Mild Parkinson's Disease: Neuropsychological and Neuroimaging Evidence. <i>Journal of Parkinsons Disease, 2016, 6, 821-832</i>	5.3	20
358	Design and Development of a Mobile Application to Explore Cognitive Skills in Parkinson's Disease Patients. <i>IFMBE Proceedings, 2016, 1150-1155</i>	0.2	1
357	Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. <i>European Journal of Neurology, 2016, 23, 1556-65</i>	6	42
356	Anatomical and functional correlates of persistent pain in Parkinson's disease. <i>Movement Disorders, 2016, 31, 1854-1864</i>	7	46

355	Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. <i>Movement Disorders</i> , 2016 , 31, 530-7	7	61
354	Switching from constant voltage to constant current in deep brain stimulation: a multicenter experience of mixed implants for movement disorders. <i>European Journal of Neurology</i> , 2016 , 23, 190-5	6	29
353	Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 207-13	4.3	8
352	Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 688-95	7	63
351	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1133-44	3.6	113
350	Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 644-9	3.6	58
349	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 287-91	3.6	72
348	Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait. <i>Neurological Sciences</i> , 2015 , 36, 1683-6	3.5	21
347	Targeting pain in Parkinson's disease. <i>Lancet Neurology, The</i> , 2015 , 14, 1144-5	24.1	15
346	A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. <i>European Journal of Neurology</i> , 2015 , 22, 1184-91	6	57
345	Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1273-7	3.6	23
344	Double-blind Randomized Trial of tDCS Versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive Training. <i>Brain Stimulation</i> , 2015 , 8, 1223-5	5.1	45
343	Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1393-7	3.6	22
342	Novel formulations and modes of delivery of levodopa. <i>Movement Disorders</i> , 2015 , 30, 114-20	7	58
341	Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 281-94	4.1	44
340	Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2015 , 30, 1237-47	7	52
339	Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report. <i>Movement Disorders</i> , 2015 , 30, 1148-9	7	18
338	King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. <i>Movement Disorders</i> , 2015 , 30, 1623-31	7	131

337	A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 170-174	2.2	9
336	Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. <i>European Journal of Neurology</i> , 2015 , 22, 1400-7	6	52
335	The neural correlates of spatial and object working memory in elderly and Parkinson's disease subjects. <i>Behavioural Neurology</i> , 2015 , 2015, 123636	3	11
334	The "gender factor" in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study. <i>Scientific World Journal, The</i> , 2015 , 2015, 787451	2.2	38
333	Overground robot assisted gait trainer for the treatment of drug-resistant freezing of gait in Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2015 , 355, 75-8	3.2	18
332	"Gunslinger's gait": a new cause of unilaterally reduced arm swing. <i>BMJ, The</i> , 2015 , 351, h6141	5.9	11
331	The efficacy of oral adenosine A(2A) antagonist istradefylline for the treatment of moderate to severe Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 1383-90	4.3	29
330	EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 510-6	7	161
329	Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 231-5	3.6	99
328	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , 2015 , 30, 150-9	7	71
327	Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. <i>Neurological Sciences</i> , 2015 , 36, 935-43	3.5	5
326	Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 394-9	3.6	62
325	Novel levodopa formulations in the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2014 , 14, 143-9	4.3	20
324	Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014 , 29, 857-67	7	148
323	Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 217-21	3.6	17
322	Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 27-31	3.6	56
321	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. <i>Lancet Neurology, The</i> , 2014 , 13, 141-9	24.1	425
320	Early DEtection of wEaring off in Parkinson disease: the DEEP study. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 204-11	3.6	90

319	The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease. <i>Neurological Sciences</i> , 2014 , 35, 73-7	3.5	8
318	Peripheral nervous system involvement in Parkinson's disease: evidence and controversies. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1329-34	3.6	45
317	Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1231-5	3.6	46
316	Adenosine A2A receptor antagonists in Parkinson's disease: still in the running. <i>Lancet Neurology</i> , 2014 , 13, 748-9	24.1	15
315	Buckwheat achenes antioxidant profile modulates <i>Aspergillus flavus</i> growth and aflatoxin production. <i>International Journal of Food Microbiology</i> , 2014 , 189, 1-10	5.8	31
314	Validation of the Italian version of Parkinson's disease-cognitive rating scale (PD-CRS). <i>Neurological Sciences</i> , 2014 , 35, 537-44	3.5	15
313	Parkinson disease: Can dopamine transporter imaging define early PD?. <i>Nature Reviews Neurology</i> , 2014 , 10, 432-3	15	9
312	Reasons for hospitalization in Parkinson's disease: a case-control study. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 488-92; discussion 488	3.6	27
311	Multiple system atrophy as emerging template for accelerated drug discovery in Synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 793-9	3.6	18
310	Grey matter changes in cognitively impaired Parkinson's disease patients. <i>PLoS ONE</i> , 2014 , 9, e85595	3.7	49
309	Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. <i>Frontiers in Cellular Neuroscience</i> , 2014 , 8, 156	6.1	119
308	Dermoscopic features and follow-up changes of acral melanocytic naevi in childhood and adolescence. <i>British Journal of Dermatology</i> , 2014 , 170, 374-81	4	11
307	Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 32-6	3.6	15
306	Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. <i>Neurological Sciences</i> , 2013 , 34, 683-7	3.5	85
305	Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features. <i>Neurological Sciences</i> , 2013 , 34, 621-7	3.5	19
304	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. <i>Journal of Neurology</i> , 2013 , 260, 2701-14	5.5	102
303	Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. <i>Journal of Neurology</i> , 2013 , 260, 1731-42	5.5	20
302	Patients with rest-tremor and scans with ipsilateral dopaminergic deficit. <i>Journal of Neurology</i> , 2013 , 260, 1132-5	5.5	9

301	Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson's disease. <i>Neurological Sciences</i> , 2013 , 34, 1751-8	3.5	10
300	Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. <i>Journal of Neural Transmission</i> , 2013 , 120, 1553-8	4.3	51
299	A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. <i>Journal of Neural Transmission</i> , 2013 , 120, 613-8	4.3	60
298	Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items". <i>Neurological Sciences</i> , 2013 , 34, 2015-22	3.5	21
297	Effects of rotigotine on Parkinson's disease-related sleep disturbances. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 2571-80	4	5
296	Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 1130-5	3.6	14
295	Rapid onset of efficacy of rasagiline in early Parkinson's disease. <i>Neurological Sciences</i> , 2013 , 34, 2007-13	3.5	3
294	EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. <i>European Journal of Neurology</i> , 2013 , 20, 16-34	6	299
293	Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease. <i>Journal of Neurology</i> , 2013 , 260, 253-9	5.5	52
292	Is there room for new non-dopaminergic treatments in Parkinson's disease?. <i>Journal of Neural Transmission</i> , 2013 , 120, 349-52	4.3	4
291	Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 557-9	3.6	26
290	Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013 , 120, 627-33	4.3	35
289	Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 501-7 ; discussion 501	3.6	77
288	Spinal cord stimulation for the treatment of sensory symptoms in advanced Parkinson's disease. <i>Neuromodulation</i> , 2013 , 16, 276-9	3.1	29
287	Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 660-5	3.6	94
286	Diagnosis of possible mild cognitive impairment in Parkinson's disease: validity of the SCOPA-Cog. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 1160-3	3.6	22
285	Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives. <i>Neurology</i> , 2013 , 81, 854	6.5	1
284	A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. <i>PLoS ONE</i> , 2013 , 8, e57221	3.7	73

283	Anatomical correlates of cognitive functions in early Parkinson's disease patients. <i>PLoS ONE</i> , 2013 , 8, e64222	3.7	42
282	Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-Cog). <i>Functional Neurology</i> , 2013 , 28, 121-5	2.2	5
281	Movement disorders: towards new therapies in Parkinson's disease. <i>Lancet Neurology</i> , 2012 , 11, 7-8	24.1	
280	Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes. <i>Movement Disorders</i> , 2012 , 27, 1552-5	7	3
279	Successful subthalamic stimulation in genetic Parkinson's disease caused by duplication of the β synuclein gene. <i>Journal of Neurology</i> , 2012 , 259, 165-7	5.5	19
278	Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012 , 18 Suppl 1, S120-2	3.6	15
277	2.135 CHARACTERISING NON MOTOR PATTERNS OF EARLY MORNING OFF PERIODS IN PARKINSON'S DISEASE: AN INTERNATIONAL STUDY. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, S110	3.6	2
276	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2012 , 259, 1639-47	5.5	153
275	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. <i>Journal of Neurology</i> , 2012 , 259, 2621-31	5.5	154
274	Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. <i>Neurological Sciences</i> , 2012 , 33, 1319-27	3.5	21
273	Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 397-9	3.6	52
272	The relationship between cerebral vascular disease and parkinsonism: The VADO study. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 775-80	3.6	49
271	High-rate production of functional nanostructured films and devices by coupling flame spray pyrolysis with supersonic expansion. <i>Nanotechnology</i> , 2012 , 23, 185603	3.4	21
270	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012 , 33, 585-93	3.5	15
269	Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. <i>Neurological Sciences</i> , 2012 , 33, 689-94	3.5	16
268	Validation of a home environment test battery for supporting assessments in advanced Parkinson's disease. <i>Neurological Sciences</i> , 2012 , 33, 831-8	3.5	11
267	Exploring composites based on PPO blend as ablative thermal protection systems [Part II: The role of equiaxial fillers. <i>Composite Structures</i> , 2012 , 94, 1060-1066	5.3	9
266	Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. <i>Clinical Neuropharmacology</i> , 2012 , 35, 205-7	1.4	48

265	Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 76-82	5.5	64
264	Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. <i>Functional Neurology</i> , 2012 , 27, 147-54	2.2	28
263	Repetitive transcranial magnetic stimulation in the treatment of dystonia 2012 , 501-511		2
262	Pharmacokinetic evaluation of pramipexole. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 1307-14	5.5	15
261	Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. <i>Journal of the Neurological Sciences</i> , 2011 , 310, 64-9	3.2	57
260	Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. <i>NeuroImage</i> , 2011 , 54, 1244-53	7.9	176
259	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011 , 43, 699-705	36.3	386
258	Handbook of Non-Motor Symptoms in Parkinson's Disease 2011 ,		5
257	Cortical visual evoked potentials recorded after optic tract near field stimulation during GPI-DBS in non-cooperative patients. <i>Clinical Neurology and Neurosurgery</i> , 2011 , 113, 119-22	2	5
256	Parkinson's disease: the non-motor issues. <i>Parkinsonism and Related Disorders</i> , 2011 , 17, 717-23	3.6	258
255	Bladder Dysfunction 2011 , 67-72		
254	Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. <i>Cardiovascular Therapeutics</i> , 2011 , 29, 404-10	3.3	15
253	The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation project. <i>Parkinson's Disease</i> , 2011 , 2011, 125271	2.6	11
252	Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 297-302	3.1	13
251	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. <i>PLoS ONE</i> , 2011 , 6, e18301	3.7	73
250	Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). <i>Archives of Neurology</i> , 2011 , 68, 223-30		73
249	miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. <i>Cell Death and Differentiation</i> , 2011 , 18, 1628-39	12.7	352
248	Low scan rate DSC study of the monoclinic-tetragonal transition in zirconia. <i>Thermochimica Acta</i> , 2011 , 524, 18-22	2.9	5

247	The conundrum of neuroprotection in Parkinson's disease. <i>Lancet Neurology, The</i> , 2011 , 10, 396-7	24.1	1
246	Pathological gambling in Parkinson's disease: disease related or drug related?. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 809-14	4.3	7
245	A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. <i>Journal of Neurology</i> , 2011 , 258, 579-85	5.5	94
244	What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?. <i>Journal of Neural Transmission</i> , 2011 , 118, 907-14	4.3	16
243	Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. <i>Movement Disorders</i> , 2011 , 26, 225-33	7	93
242	Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 464-8	7	115
241	Wearing-off scales in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , 2011 , 26, 2169-75	7	68
240	Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. <i>Journal of Parkinson's Disease</i> , 2011 , 1, 197-203	5.3	83
239	Sleep in genetically confirmed pantothenate kinase-associated neurodegeneration: a video-polysomnographic study. <i>Parkinson's Disease</i> , 2010 , 2010, 342834	2.6	9
238	Cognitive bizarreness in the dream and waking mentation of nonpsychotic patients with Parkinson's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2010 , 22, 395-400	2.7	7
237	Role of pramipexole in the management of Parkinson's disease. <i>CNS Drugs</i> , 2010 , 24, 829-41	6.7	39
236	Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. <i>CNS Drugs</i> , 2010 , 24, 119-29	6.7	49
235	SPECT Imaging in Movement Disorders 2010 , 140-147		
234	The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2010 , 112, 65-7	2	11
233	alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2010 , 16, 228-31	3.6	30
232	Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. <i>European Neuropsychopharmacology</i> , 2010 , 20, 683-7	1.2	19
231	Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. <i>Clinical Neuropharmacology</i> , 2010 , 33, 61-6	1.4	12
230	Levodopa in the treatment of Parkinson's disease: an old drug still going strong. <i>Clinical Interventions in Aging</i> , 2010 , 5, 229-38	4	160

229	Single-photon emission computed tomography in diagnosis and differential diagnosis of Parkinson's disease. <i>Neurodegenerative Diseases</i> , 2010 , 7, 319-29	2.3	13
228	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010 , 257, 5-14	5.5	115
227	Cognitive status of patients with Parkinson's disease and pathological gambling. <i>Journal of Neurology</i> , 2010 , 257, 247-52	5.5	42
226	The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. <i>Journal of Neurology</i> , 2010 , 257, 1882-9	5.5	35
225	Continuous dopaminergic delivery in Parkinson's disease. <i>Journal of Neurology</i> , 2010 , 257, S305-8	5.5	16
224	Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. <i>Neurological Sciences</i> , 2010 , 31, 35-40	3.5	33
223	Imaging for early differential diagnosis of parkinsonism. <i>Lancet Neurology, The</i> , 2010 , 9, 130-1	24.1	9
222	Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. <i>Neurobiology of Disease</i> , 2010 , 39, 98-104	7.5	117
221	Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease. <i>World Neurosurgery</i> , 2010 , 73, 338-44	2.1	67
220	Imaging essential tremor. <i>Movement Disorders</i> , 2010 , 25, 679-86	7	64
219	Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. <i>Movement Disorders</i> , 2010 , 25, 50-6	7	27
218	Multilayer SiC for thermal protection system of space vehicles with decreased thermal conductivity through the thickness. <i>Journal of the European Ceramic Society</i> , 2010 , 30, 1833-1840	6	32
217	Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. <i>Functional Neurology</i> , 2010 , 25, 21-5	2.2	9
216	Apomorphine and levodopa infusion therapies for advanced Parkinson's disease. <i>Journal of Movement Disorders</i> , 2009 , 2, 4-9	2.9	10
215	A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. <i>Lancet Neurology, The</i> , 2009 , 8, 929-37	24.1	145
214	Adherence to antiparkinson medication in a multicenter European study. <i>Movement Disorders</i> , 2009 , 24, 826-32	7	131
213	Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. <i>Movement Disorders</i> , 2009 , 24, 1028-33	7	42
212	Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. <i>Movement Disorders</i> , 2009 , 24, 1468-74	7	191

211	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1641-9	7	919
210	Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. <i>Journal of Neurology</i> , 2009 , 256, 910-5	5.5	55
209	Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: a prospective case-control study. <i>Clinical Neurology and Neurosurgery</i> , 2009 , 111, 140-6	2	36
208	Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 327-8	3.6	30
207	Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 576-81	3.6	39
206	Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. <i>Drug Safety</i> , 2009 , 32, 475-88	5.1	66
205	Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. <i>Expert Review of Neurotherapeutics</i> , 2009 , 9, 859-67	4.3	62
204	Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15 Suppl 4, S97-100	3.6	50
203	Non-motor Symptoms in Parkinson's Disease. <i>European Neurological Review</i> , 2009 , 4, 25	0.5	3
202	A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onset. <i>Neurobiology of Disease</i> , 2008 , 31, 102-9	7.5	24
201	MoSi2 laminate processed by tape casting: Microstructure and mechanical properties' investigation. <i>Intermetallics</i> , 2008 , 16, 758-768	3.5	12
200	"How many Parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire" by Morgante L, Morgante F, Moro E, et al., published online 7 March 2007. <i>Parkinsonism and Related Disorders</i> , 2008 , 14, 264-5; author reply 266-7	3.6	
199	Parkin analysis in early onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008 , 14, 326-33	3.6	37
198	Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. <i>Archives of Neurology</i> , 2008 , 65, 1191-4		186
197	Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. <i>Neurodegenerative Diseases</i> , 2008 , 5, 244-6	2.3	83
196	Functional abnormalities underlying pathological gambling in Parkinson disease. <i>Archives of Neurology</i> , 2008 , 65, 1604-11		109
195	Single photon-emission computed tomography imaging in early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 1853-64	4.3	4
194	Striatal dopamine transporter abnormalities in patients with essential tremor. <i>Nuclear Medicine Communications</i> , 2008 , 29, 349-53	1.6	59

193	COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. <i>Neuropsychiatric Disease and Treatment</i> , 2008 , 4, 1-9	3.1	47
192	Cerebral activity modulation by extradural motor cortex stimulation in Parkinson's disease: a perfusion SPECT study. <i>European Journal of Neurology</i> , 2008 , 15, 22-8	6	12
191	The PRIAMO study: background, methods and recruitment. <i>Neurological Sciences</i> , 2008 , 29, 61-5	3.5	24
190	Dopamine agonist-based strategies in the treatment of Parkinson's disease. <i>Neurological Sciences</i> , 2008 , 29 Suppl 5, S371-4	3.5	25
189	Clinical experience of tolcapone in advanced Parkinson's disease. <i>Neurological Sciences</i> , 2008 , 29 Suppl 5, S380-2	3.5	5
188	Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. <i>Neurological Sciences</i> , 2008 , 29 Suppl 5, S387-8	3.5	21
187	The rationale for improved integration between home care and neurology hospital services in patients with advanced Parkinson's disease. <i>Neurological Sciences</i> , 2008 , 29 Suppl 5, S392-6	3.5	12
186	Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study. <i>Journal of Neural Transmission</i> , 2008 , 115, 721-9	4.3	44
185	The relationship between impulsivity and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 411-5	7	119
184	[123I]FP-CIT SPET imaging in drug-induced Parkinsonism. <i>Movement Disorders</i> , 2008 , 23, 1825-9	7	41
183	Predictive value of nigrostriatal dysfunction in isolated tremor: a clinical and SPECT study. <i>Movement Disorders</i> , 2008 , 23, 2049-54	7	31
182	Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. <i>Movement Disorders</i> , 2008 , 23, 2202-9	7	41
181	PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008 , 29, 565	4.7	58
180	Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. <i>Human Mutation</i> , 2007 , 28, 98	4.7	51
179	Extradural motor cortex stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 111-4	7	40
178	Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. <i>Movement Disorders</i> , 2007 , 22, 275-8	7	38
177	Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. <i>Movement Disorders</i> , 2007 , 22, 1145-9	7	218
176	Role of DAT-SPECT in the diagnostic work up of parkinsonism. <i>Movement Disorders</i> , 2007 , 22, 1229-38	7	180

175	Dopa-responsive pseudo-orthostatic tremor in parkinsonism. <i>Movement Disorders</i> , 2007 , 22, 1652-6	7	39
174	Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure. <i>European Journal of Neurology</i> , 2007 , 14, 297-9	6	8
173	Clinical and imaging characterization of a patient with idiopathic progressive ataxia and palatal tremor. <i>European Journal of Neurology</i> , 2007 , 14, 944-6	6	11
172	Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. <i>Lancet Neurology</i> , 2007 , 6, 826-9	24.1	200
171	Bioactive Sulforaphane from in vitro Propagated Brassica Seedlings. <i>Engineering in Life Sciences</i> , 2007 , 7, 275-277	3.4	1
170	Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. <i>Neurogenetics</i> , 2007 , 8, 103-9	3	30
169	Daytime somnolence and night sleep disturbances in Parkinson's disease: background and future treatment prospective. <i>Neurological Sciences</i> , 2007 , 28 Suppl 1, S6-8	3.5	4
168	Valvular heart disease and the use of dopamine agonists for Parkinson's disease. <i>New England Journal of Medicine</i> , 2007 , 356, 39-46	59.2	705
167	[123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. <i>NeuroReport</i> , 2007 , 18, 1499-502	1.7	48
166	Anatomical identification of active contacts in subthalamic deep brain stimulation. <i>World Neurosurgery</i> , 2007 , 67, 140-6; discussion 146-7		33
165	Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: an ECD-SPECT study. <i>Parkinsonism and Related Disorders</i> , 2007 , 13, 290-4	3.6	50
164	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , 2007 , 13, 528-31	3.6	57
163	Continuous dopaminergic stimulation--from theory to clinical practice. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl, S24-8	3.6	32
162	New strategies in motor parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl 3, S446-9	3.6	11
161	The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. <i>Neuropsychiatric Disease and Treatment</i> , 2007 , 3, 287-92	3.1	7
160	Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report. <i>Movement Disorders</i> , 2006 , 21, 270-3	7	39
159	Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. <i>Movement Disorders</i> , 2006 , 21, 417-8	7	25
158	Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. <i>Movement Disorders</i> , 2006 , 21, 1119-22	7	86

157	Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. <i>Movement Disorders</i> , 2006 , 21, 1144-7	7	35
156	Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 450-3	5.5	103
155	Parkinson's disease, chronic hydrocarbon exposure and striatal neuronal damage: a 1-H MRS study. <i>NeuroToxicology</i> , 2006 , 27, 164-8	4.4	21
154	Clinical correlates and cognitive underpinnings of verbal fluency impairment after chronic subthalamic stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006 , 12, 289-95	3.6	64
153	LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. <i>Parkinsonism and Related Disorders</i> , 2006 , 12, 410-9	3.6	85
152	Bilateral subthalamic deep brain stimulation in a patient with Parkinson's disease who had previously undergone thalamotomy and autologous adrenal grafting in the caudate nucleus: case report. <i>Neurosurgery</i> , 2006 , 59, E1140; discussion E1140	3.2	6
151	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. <i>European Journal of Human Genetics</i> , 2006 , 14, 322-31	5.3	134
150	Channeling-based collimators for generation of microbeams produced by silicon micromachining technology. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2006 , 252, 11-15	1.2	1
149	Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. <i>Journal of Neurology</i> , 2006 , 253, 601-7	5.5	209
148	Comparative analysis of visual and semi-quantitative assessment of striatal [¹²³ I]FP-CIT-SPET binding in Parkinson's disease. <i>Neurological Sciences</i> , 2006 , 27, 397-401	3.5	36
147	DN1 ECONOMIC EVALUATION OF SPECT-DATSCAN IN THE DIAGNOSIS OF PATIENTS WITH CLINICALLY UNCERTAIN PARKINSONISM IN ITALY. <i>Value in Health</i> , 2005 , 8, A14	3.3	2
146	Tailoring of silicon crystals for relativistic-particle channeling. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2005 , 234, 40-46	1.2	34
145	Novel parkin mutations detected in patients with early-onset Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 424-431	7	51
144	Brain SPECT imaging in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2005 , 112, 1635-45	4.3	42
143	[¹²³ I]FP-CIT SPECT findings in two patients with Hallervorden-Spatz disease with homozygous mutation in PANK2 gene. <i>Neurology</i> , 2005 , 64, 167-8	6.5	13
142	The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. <i>Journal of Medical Genetics</i> , 2005 , 42, e65	5.8	141
141	Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. <i>Neurology</i> , 2005 , 65, 1971-3	6.5	31
140	Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. <i>Neurology</i> , 2005 , 65, 87-95	6.5	276

139	Pharmacological and PET studies in patient's with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications. <i>Journal of Neural Transmission</i> , 2004 , 111, 497-509	4.3	18
138	Pramipexole-treated Parkinson's disease during pregnancy. <i>Movement Disorders</i> , 2004 , 19, 1114-5	7	33
137	The effect of doping LiMn2O4 spinel on its use as a cathode in Li-ion batteries: neutron diffraction and electrochemical studies. <i>Journal of Physics and Chemistry of Solids</i> , 2004 , 65, 29-37	3.9	34
136	Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. <i>Archives of Gerontology and Geriatrics</i> , 2004 , 291-6	4	42
135	Deep brain stimulation and its effect on sleep in Parkinson's disease. <i>Sleep Medicine</i> , 2004 , 5, 211-4	4.6	26
134	PET and SPECT functional imaging in Parkinson's disease. <i>Sleep Medicine</i> , 2004 , 5, 201-6	4.6	30
133	Evaluation of cefepime kinetic variables and milk production volume in goats. <i>Arquivo Brasileiro De Medicina Veterinaria E Zootecnia</i> , 2004 , 56, 116-118	0.3	1
132	MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. <i>American Journal of Neuroradiology</i> , 2004 , 25, 927-32	4.4	79
131	123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. <i>Neurological Sciences</i> , 2003 , 24, 149-50	3.5	122
130	Brain flow changes before and after deep brain stimulation of the subthalamic nucleus in Parkinson's disease. <i>Neurological Sciences</i> , 2003 , 24, 151-2	3.5	16
129	Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. <i>Neurological Sciences</i> , 2003 , 24, 174-5	3.5	29
128	Deep brain stimulation for the treatment of Parkinson's disease: the experience of the Neurosurgical Department in Monza. <i>Neurological Sciences</i> , 2003 , 24 Suppl 1, S43-4	3.5	17
127	MRI indirect stereotactic targeting for deep brain stimulation in Parkinson's disease. <i>Journal of Neurosurgical Sciences</i> , 2003 , 47, 26-32	1.3	8
126	Functional neuroimaging (PET and SPECT) in the selection and assessment of patients with Parkinson's disease undergoing deep brain stimulation. <i>Journal of Neurosurgical Sciences</i> , 2003 , 47, 40-6 ^{1.3}		9
125	Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. <i>Movement Disorders</i> , 2002 , 17, 1265-70	7	77
124	Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2). <i>Neurological Sciences</i> , 2002 , 23 Suppl 2, S51-2	3.5	16
123	Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. <i>Neurological Sciences</i> , 2002 , 23 Suppl 2, S59-60	3.5	32
122	Geometrically Nonlinear Cantilever under Stochastic Loading Vectors. <i>Nonlinear Dynamics</i> , 2002 , 28, 83-102	5	7

121	Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease. <i>Journal of Computer Assisted Tomography</i> , 2002 , 26, 266-71	2.2	41
120	The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)-tropane in patients with movement disorders. <i>Nuclear Medicine Communications</i> , 2002 , 23, 1047-55	1.6	20
119	Morbo di Parkinson, esposizione a sostanze tossiche e nuclei della base Uno studio mediante spettroscopia protonica a risonanza magnetica. <i>The Neuroradiology Journal</i> , 2001 , 14, 47-48		1
118	Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. <i>Neurological Sciences</i> , 2001 , 22, 45-6	3.5	56
117	The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. <i>Neurological Sciences</i> , 2001 , 22, 47-8	3.5	74
116	A morphological study of SEI film on graphite electrodes. <i>Journal of Power Sources</i> , 2001 , 97-98, 146-150	3.9	29
115	Emergence of ocular dominance columns in cat visual cortex by 2 weeks of age. <i>Journal of Comparative Neurology</i> , 2001 , 430, 235-49	3.4	98
114	Factors shaping the corpus callosum. <i>Journal of Comparative Neurology</i> , 2001 , 433, 437-40	3.4	13
113	Functional correlates of pallidal stimulation for Parkinson's disease. <i>Annals of Neurology</i> , 2001 , 49, 155-64	3.4	96
112	Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. <i>Brain</i> , 2001 , 124, 1601-9	11.2	109
111	Infusion of nerve growth factor (NGF) into kitten visual cortex increases immunoreactivity for NGF, NGF receptors, and choline acetyltransferase in basal forebrain without affecting ocular dominance plasticity or column development. <i>Neuroscience</i> , 2001 , 108, 569-85	3.9	18
110	Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. <i>Journal of Nuclear Medicine</i> , 2001 , 42, 1591-5	8.9	133
109	Benzodiazepine receptor binding in Huntington's disease: [11C]Flumazenil uptake measured using positron emission tomography. <i>Annals of Neurology</i> , 2000 , 47, 644-648	9.4	56
108	Tolerability of paroxetine in Parkinson's disease: a prospective study. <i>Movement Disorders</i> , 2000 , 15, 986-9	7	86
107	Wild-type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells. <i>Journal of Investigative Dermatology</i> , 2000 , 114, 1188-94	4.3	37
106	Patterns of regional brain activation associated with different forms of motor learning. <i>Brain Research</i> , 2000 , 871, 127-45	3.7	299
105	Hydrocarbon exposure and Parkinson's disease. <i>Neurology</i> , 2000 , 55, 667-73	6.5	58
104	The metabolic topography of essential blepharospasm: a focal dystonia with general implications. <i>Neurology</i> , 2000 , 55, 673-7	6.5	137

103	Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. <i>Annals of Neurology</i> , 2000 , 47, 644-8	9.4	14
102	Increased cerebral iron uptake in Wilson's disease: a 52Fe-citrate PET study. <i>Journal of Nuclear Medicine</i> , 2000 , 41, 781-7	8.9	43
101	Anatomical correlates of functional plasticity in mouse visual cortex. <i>Journal of Neuroscience</i> , 1999 , 19, 4388-406	6.6	261
100	An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication. <i>Journal of Neural Transmission</i> , 1999 , 106, 925-9	4.3	47
99	Positron emission tomographic studies in restless legs syndrome. <i>Movement Disorders</i> , 1999 , 14, 141-5	7	149
98	Reproducibility of regional metabolic covariance patterns: comparison of four populations. <i>Journal of Nuclear Medicine</i> , 1999 , 40, 1264-9	8.9	90
97	Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. <i>Clinical Neuropharmacology</i> , 1999 , 22, 277-80	1.4	9
96	[11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. <i>Annals of Neurology</i> , 1998 , 43, 253-5	9.4	107
95	Functional brain networks in DYT1 dystonia. <i>Annals of Neurology</i> , 1998 , 44, 303-12	9.4	263
94	D2 receptor binding in dopa-responsive dystonia. <i>Annals of Neurology</i> , 1998 , 44, 758-62	9.4	27
93	Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. <i>Movement Disorders</i> , 1998 , 13, 268-74	7	92
92	Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys. <i>Parkinsonism and Related Disorders</i> , 1998 , 4, 147-58	3.6	9
91	The metabolic anatomy of tremor in Parkinson's disease. <i>Neurology</i> , 1998 , 51, 803-10	6.5	91
90	Factors Affecting the Stabilization of Mn Spinel Capacity upon Staring and Cycling at High Temperatures. <i>Journal of the Electrochemical Society</i> , 1998 , 145, 2726-2732	3.9	43
89	Cerebral glucose metabolism in women with panic disorder. <i>American Journal of Psychiatry</i> , 1998 , 155, 1178-83	11.9	112
88	Effect of sensory disuse on geniculate afferents to cat visual cortex. <i>Visual Neuroscience</i> , 1998 , 15, 401-9	1.7	31
87	Morphology of single geniculocortical afferents and functional recovery of the visual cortex after reverse monocular deprivation in the kitten. <i>Journal of Neuroscience</i> , 1998 , 18, 9896-909	6.6	57
86	Brain Networks of Motor Behavior Assessed by Principal Component Analysis 1998 , 165-172		2

85	Reproducibility of Regional Metabolic Covariance Patterns: Comparison of Four Populations 1998 , 247-252	2
84	Neutral Amino Acids Influence [18F]Fluorodopa Quantification 1998 , 379-385	
83	Dopamine transporter imaging with fluorine-18-FPCIT and PET. <i>Journal of Nuclear Medicine</i> , 1998 , 39, 1521-30	8.9 125
82	Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. <i>Brain</i> , 1997 , 120 (Pt 12), 2187-95	11.2 169
81	Metabolic correlates of pallidal neuronal activity in Parkinson's disease. <i>Brain</i> , 1997 , 120 (Pt 8), 1315-24	11.2 100
80	Lithiated MnO ₂ Phases as Cathodes for 3 V Li and Li-Ion Cells. <i>Journal of the Electrochemical Society</i> , 1997 , 144, 1553-1559	3.9 14
79	Preoperative indicators of clinical outcome following stereotaxic pallidotomy. <i>Neurology</i> , 1997 , 49, 1083-90	6.9 55
78	The metabolic anatomy of Tourette's syndrome. <i>Neurology</i> , 1997 , 48, 927-34	6.5 140
77	Doped LiMn Spinels: Physical/Chemical Characteristics and Electrochemical Performance in Li Batteries. <i>Chemistry of Materials</i> , 1997 , 9, 1443-1450	9.6 73
76	Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. <i>Experimental Cell Research</i> , 1997 , 236, 76-85	4.2 187
75	Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). <i>European Neuropsychopharmacology</i> , 1997 , 7, 9-24	1.2 271
74	Cerebral metabolic changes (18F-FDG PET) during selective anterior temporal lobe amobarbital test. <i>European Neurology</i> , 1997 , 38, 268-75	2.1 8
73	Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition. <i>Brain Research</i> , 1997 , 767, 45-54	3.7 10
72	Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. <i>Movement Disorders</i> , 1997 , 12, 33-8	7 191
71	Cerebral glucose metabolism in patients with spasmodic torticollis. <i>Movement Disorders</i> , 1997 , 12, 704-87	65
70	Temporal lobe epilepsy: correlation of proton magnetic resonance spectroscopy and 18F-fluorodeoxyglucose positron emission tomography. <i>Magnetic Resonance in Medicine</i> , 1997 , 37, 18-23	4.4 35
69	Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa. <i>Acta Neurologica Scandinavica</i> , 1996 , 93, 387-92	3.8 25
68	Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. <i>Brain</i> , 1996 , 119 (Pt 6), 2085-95	11.2 280

67	Photoemission from atomic and molecular adsorbates on Rh(100). <i>Surface Science</i> , 1996 , 347, 53-62	1.8	38
66	Radiosynthesis of [¹¹ C]brofaromine, a potential tracer for imaging monoamine oxidase A. <i>Nuclear Medicine and Biology</i> , 1996 , 23, 229-34	2.1	11
65	Radiosynthesis of [¹⁸ F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. <i>Nuclear Medicine and Biology</i> , 1996 , 23, 999-1004	2.1	73
64	Plasticity of geniculocortical afferents following brief or prolonged monocular occlusion in the cat. <i>Journal of Comparative Neurology</i> , 1996 , 369, 64-82	3.4	109
63	Storage characteristics of cathodes for Li-ion batteries. <i>Electrochimica Acta</i> , 1996 , 41, 2683-2689	6.7	137
62	Effect of partial Ga ³⁺ substitution for Mn ³⁺ in LiMn ₂ O ₄ on its behaviour as a cathode for Li cells. <i>Journal of Electroanalytical Chemistry</i> , 1996 , 410, 115-118	4.1	22
61	Impedance study on the reactivity of gel polymer electrolytes towards a lithium electrode. <i>Journal of Power Sources</i> , 1996 , 58, 139-144	8.9	26
60	First results from the high energy resolution photoemission beam line at ELETTRA. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 1995 , 364, 374-379	1.2	51
59	Synthesis of Mn spinels from different polymorphs of MnO ₂ . <i>Journal of Power Sources</i> , 1995 , 56, 37-43	8.9	23
58	Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. <i>Archives of Neurology</i> , 1995 , 52, 1183-90		155
57	Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[¹⁸ F]fluoro-L-dopa in rhesus monkey. <i>Nuclear Medicine and Biology</i> , 1995 , 22, 921-7	2.1	14
56	n-Hexane-induced parkinsonism: pathogenetic hypotheses. <i>Movement Disorders</i> , 1995 , 10, 279-82	7	41
55	Mapping subcortical extrarelay afferents onto primary somatosensory and visual areas in cats. <i>Journal of Comparative Neurology</i> , 1995 , 362, 46-70	3.4	22
54	Lisuride and [¹¹ C]-Raclopride Interaction at the D ₂ Receptor Site 1995 , 205-214		
53	Ultrastructural evidence for synaptic interactions between thalamocortical axons and subplate neurons. <i>European Journal of Neuroscience</i> , 1994 , 6, 1729-42	3.5	115
52	[¹¹ C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D ₂ -receptors. <i>Neurology</i> , 1994 , 44, 1325-9	6.5	180
51	Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits. <i>Clinical Neuropharmacology</i> , 1994 , 17, 270-6	1.4	5
50	Comparison of ¹²³ I-IBZM SPECT and ¹¹ C-raclopride PET findings in patients with parkinsonism. <i>Nuclear Medicine Communications</i> , 1994 , 15, 806-13	1.6	35

49	Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol. <i>Journal of Neural Transmission Supplementum</i> , 1994 , 43, 123-32		5
48	Striatal dopamine D2 receptors in patients with narcolepsy measured with PET and 11C-raclopride. <i>Neurology</i> , 1994 , 44, 2102-4	6.5	24
47	Preoperative and postoperative glucose consumption in mesiobasal and lateral temporal lobe epilepsy. <i>Neurology</i> , 1994 , 44, 2125-32	6.5	61
46	Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease. <i>Neurology</i> , 1994 , 44, 1079-82	6.5	22
45	High Energy Resolution Photoemission Beam Line at ELETTRA. <i>Acta Physica Polonica A</i> , 1994 , 86, 487-495	6	1
44	Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [11C]-raclopride. <i>Annals of the New York Academy of Sciences</i> , 1993 , 695, 81-5	6.5	64
43	Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. <i>Archives of Neurology</i> , 1993 , 50, 474-80		154
42	Rapid remodeling of axonal arbors in the visual cortex. <i>Science</i> , 1993 , 260, 1819-21	33.3	440
41	T2 relaxation time in patients with Parkinson's disease. <i>Neurology</i> , 1993 , 43, 697-700	6.5	146
40	Band offsets and strain in CdTe-GaAs heterostructures. <i>Physical Review B</i> , 1993 , 48, 8899-8910	3.3	25
39	Development of individual geniculocortical arbors in cat striate cortex and effects of binocular impulse blockade. <i>Journal of Neuroscience</i> , 1993 , 13, 3549-73	6.6	223
38	Increased striatal glucose consumption in Sydenham's chorea. <i>Movement Disorders</i> , 1993 , 8, 437-44	7	34
37	Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). <i>European Journal of Clinical Pharmacology</i> , 1993 , 44, 135-40	2.8	10
36	Mesiobasal versus lateral temporal lobe epilepsy: metabolic differences in the temporal lobe shown by interictal 18F-FDG positron emission tomography. <i>Neurology</i> , 1993 , 43, 79-86	6.5	115
35	AlAs-GaAs heterojunction engineering by means of group-IV elemental interface layers. <i>Physical Review B</i> , 1992 , 45, 4528-4531	3.3	41
34	Structure and local dipole of Si interface layers in AlAs-GaAs heterostructures. <i>Physical Review B</i> , 1992 , 46, 6834-6845	3.3	42
33	Epilepsia partialis continua studied by PET. <i>Epilepsy Research</i> , 1991 , 9, 44-8	3	37
32	A procedure for the simultaneous visualization of two anterograde and different retrograde fluorescent tracers. Application to the study of the afferent-efferent organization of thalamic anterior intralaminar nuclei. <i>Journal of Neuroscience Methods</i> , 1991 , 38, 183-91	3	16

31	Epitaxial growth and interface parameters of Si layers on GaAs(001) and AlAs(001) substrates. <i>Journal of Vacuum Science & Technology an Official Journal of the American Vacuum Society B, Microelectronics Processing and Phenomena</i> , 1991 , 9, 2225		30
30	Tuning AlAs-GaAs heterostructure properties by means of MBE-grown Si interface layers. <i>Surface Science</i> , 1991 , 251-252, 82-86	1.8	13
29	Tuning AlAs-GaAs band discontinuities and the role of Si-induced local interface dipoles. <i>Physical Review B</i> , 1991 , 43, 2450-2453	3.3	118
28	Uptake of radiocesium by mushrooms. <i>Science of the Total Environment</i> , 1991 , 106, 183-90	10.2	25
27	Relation Between Putative Transmitter Phenotypes and Connectivity of Subplate Neurons During Cerebral Cortical Development. <i>European Journal of Neuroscience</i> , 1990 , 2, 744-761	3.5	100
26	Requirement for subplate neurons in the formation of thalamocortical connections. <i>Nature</i> , 1990 , 347, 179-81	50.4	505
25	Pioneer neurons and target selection in cerebral cortical development. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1990 , 55, 469-80	3.9	68
24	Effects of terguride in patients with Huntington's disease. <i>Clinical Neuropharmacology</i> , 1989 , 12, 435-9	1.4	7
23	Visual and somatosensory integration in the anterior ectosylvian cortex of the cat. <i>Brain Research</i> , 1987 , 410, 21-31	3.7	33
22	Electrophysiological evidence for interhemispheric connections in the anterior ectosylvian sulcus in the cat. <i>Experimental Brain Research</i> , 1987 , 66, 90-8	2.3	11
21	Role of Callosal Connections in the Representation of the Visual Field in the Primary Visual Cortex of the Cat 1987 , 349-366		
20	Role of Callosal Connections in the Representation of the Visual Field in the Primary Visual Cortex of the Cat 1987 , 349-366		
19	Mössbauer studies of the Umbria archeological clays. <i>Hyperfine Interactions</i> , 1986 , 29, 1133-1136	0.8	3
18	Interhemispheric influences on area 19 of the cat. <i>Experimental Brain Research</i> , 1985 , 59, 171-84	2.3	26
17	Immediate postoperative retention of visual discriminations following selective cortical lesions in the cat. <i>Behavioural Brain Research</i> , 1985 , 17, 145-62	3.4	13
16	Radon and radon daughter evaluation in a natural radioactivity survey indoors. <i>Science of the Total Environment</i> , 1985 , 45, 373-80	10.2	3
15	Indoor Exposure in a Region of Central Italy. <i>Radiation Protection Dosimetry</i> , 1984 , 7, 271-274	0.9	6
14	Binocularity in the visual cortex of the adult cat does not depend on the integrity of the corpus callosum. <i>Behavioural Brain Research</i> , 1984 , 13, 183-92	3.4	33

13	Mössbauer Study of the Pbx Sn Te System. <i>Physica Status Solidi (B): Basic Research</i> , 1983 , 120, K15-K18	1.3	2
12	Physiological organization of callosal connections of a visual lateral suprasylvian cortical area in the cat. <i>Journal of Neurophysiology</i> , 1983 , 49, 902-21	3.2	48
11	The contribution of the corpus callosum to receptive fields in the lateral suprasylvian visual areas of the cat. <i>Behavioural Brain Research</i> , 1982 , 4, 155-76	3.4	35
10	Mössbauer study of the PbxSn1125Te system. <i>Physica Status Solidi (B): Basic Research</i> , 1982 , 114, 585-588	1.3	4
9	Differences in binocular interactions between cortical areas 17 and 18 and superior colliculus of Siamese cats. <i>Journal of Comparative Neurology</i> , 1981 , 200, 597-611	3.4	16
8	Callosum-dependent binocular interactions in the lateral suprasylvian area of Siamese cats which lack binocular neurons in areas 17 and 18. <i>Brain Research</i> , 1980 , 197, 230-5	3.7	36
7	Learning and interhemispheric transfer of visual pattern discriminations following unilateral suprasylvian lesions in split-chiasm cats. <i>Experimental Brain Research</i> , 1979 , 34, 551-74	2.3	29
6	Importance of corpus callosum for visual receptive fields of single neurons in cat superior colliculus. <i>Journal of Neurophysiology</i> , 1979 , 42, 137-52	3.2	44
5	Behavioral and electrophysiological effects of unilateral optic tract section in ordinary and Siamese cats. <i>Journal of Comparative Neurology</i> , 1979 , 185, 183-202	3.4	14
4	Indirect, across-the-midline retinotectal projections and representation of ipsilateral visual field in superior colliculus of the cat. <i>Journal of Neurophysiology</i> , 1978 , 41, 285-304	3.2	36
3	Movement disorders in multiple sclerosis268-278		
2	The impact of neuropsychiatric symptoms on quality of life in Parkinson's disease255-260		
1	Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trial (Preprint)		1